Industries > Pharma > Pharma Leader Series: Top 26 Asthma & COPD Companies 2020-2030

Pharma Leader Series: Top 26 Asthma & COPD Companies 2020-2030

Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

PUBLISHED: 17 February 2020
PAGES: 177
PRODUCT CODE: PHA0713

Clear
WOOCS 2.2.1
SKU: PHA0713 Categories: , , Tags: ,

The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $60.8bn by 2030.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 177-page report you will receive 100 charts– all unavailable elsewhere.

The 177-page report provides clear detailed insight into the Top 26 asthma & COPD companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Asthma & COPD Therapies Market forecasts from 2020-2030

• Profiles of the leading 26 asthma & COPD companies:
• Adamis Pharmaceuticals Corporation
• Aerocrine (Circassia)
• ALK-Abello A/S
• Amphastar Pharmaceuticals, Inc.
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• Dimerix
• GlaxoSmithKline
• Innoviva
• Lallemand Pharma International
• Merck
• Mereo BioPharma Group plc
• MundiPharma
• Novartis
• Pulmatrix
• Respiratorius AB
• Roche
• Other companies

Top 26 Asthma & COPD Companies 2020-2030

• The content of each profile differs, depending on the organization. In general, a profile gives the following information:
• An overview and analysis of the company
• A portfolio of the company’s marketed product and product pipeline
• Financial Information
• Revenue forecast from 2020-2030
• Recent developments
• Future Outlook

• This report discusses factors that drive and restrain the asthma and COPD market.

• Key questions answered by this report:
• How is the Asthma & COPD Companies market evolving?
• What is driving and restraining the Asthma & COPD Companies market?
• What are the market shares of each segment of the overall Asthma & COPD Companies market in 2019?
• What will be the main driver for the overall market from 2019 to 2030?
• Will leading Asthma & COPD Companies broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?
• What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
• How will the industry evolve during the period between 2019 and 2030?

Visiongain’s study is intended for anyone requiring commercial analyses for the top 26 asthma & COPD therapies companies. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 26 Asthma & COPD Companies 2020-2030: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 26 Asthma & COPD Companies 2020-2030


Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 26 Asthma & COPD Companies 2020-2030


Latest Pharma news

Visiongain’s analysis indicates that total revenue on Tuberculosis Treatment Drugs Market will be $1,080 million in 2020 due to the World Health Organization strong commitment towards ending TB leading to increase in funding for the research and development both in developed as well and under-developed markets

Due to maturity of generic drug market, companies are moving away from generics drug into therapeutic market by building strong portfolio for development of anti-tuberculosis drug emphasizing all types of TB cases.

06 April 2020

READ

The Global Wound Care Market Is Set to Boom, Particularly in Emerging Economies

The global wound care market is big, and only set to grow bigger.  Currently, estimates show a CAGR of 4.6% in the years to come, with the overall market growing from US$19.8 billion in 2019 to US$24.8 billion by 2024.  The industry is ripe with opportunity, with that growth coming from several factors – but most especially growth in emerging …

30 March 2020

READ

“The global nasal drug delivery technology market is estimated to have reached $44,385 million in 2019” says new Visiongain report

Nasal Sprays segment held the largest market share of the global nasal drug delivery technology market in 2019.

30 March 2020

READ

“Global Stem Cell Technologies and Applications market set to grow to $10903.0m by 2025” says new Visiongain report

New technologies will be needed to ensure that scaling-up of manufacturing operations can be done effectively once stem cell treatments enter the market.

24 March 2020

READ

Categories

Category